We are always evolving in an ever-changing industry.

Keep up-to-date with PrECOG by visiting our news page regularly.

Durvalumab added to standard chemotherapy improved overall survival in mesothelioma

Phase 2 trial PrE0505 selected for oral presentation at ASCO 2020; data signals the combination should advance to a randomized phase 3 study For Immediate Release May 20, 2020 Contact Diane Dragaud Director of Communications (215) 789-3631 Inquire by email Philadelphia, PA—PrECOG, LLC is reporting clinical efficacy and biomarker analyses from its single-arm phase two […]